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G protein-coupled receptor (GPR)35 is highly expressed in the gastro-intestinal tract, pre-
dominantly in colon epithelial cells (CEC), and has been associated with inflammatory bowel
diseases (IBD), suggesting a role in gastrointestinal inflammation. The enterotoxigenic Bac-
teroides fragilis (ETBF) toxin (BFT) is an important virulence factor causing gut inflammation
in humans and animal models. We identified that BFT signals through GPR35. Blocking
GPR35 function in CECs using the GPR35 antagonist ML145, in conjunction with shRNA
knock-down and CRISPRcas-mediated knock-out, resulted in reduced CEC-response to BFT
as measured by E-cadherin cleavage, beta-arrestin recruitment and IL-8 secretion. Impor-
tantly, GPR35 is required for the rapid onset of ETBF-induced colitis in mouse models.
GPR35-deficient mice showed reduced death and disease severity compared to wild-type
C57Bl6 mice. Our data support a role for GPR35 in the CEC and mucosal response to BFT and
underscore the importance of this molecule for sensing ETBF in the colon.
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The microbiome has been demonstrated to make consider-able contributions to both health and disease. Genome-wide association studies (GWAS) and microbiome
sequencing have provided powerful tools to study the etiologic
importance of host genetic susceptibility and unbalanced gut
microbiota to promote inflammatory bowel diseases (IBD).
However, understanding how these factors work together to
trigger IBD remains a challenge.
Several studies have identified an association between enter-
otoxigenic Bacteroides fragilis (ETBF) that secretes the Bacteroides
fragilis toxin (BFT) and human IBD, as well as colorectal cancer
(CRC)1–3. ETBF is associated with acute diarrhea in children and
adults, and asymptomatic colonization is likely to be frequent, at
least, in some populations (~0–55%, depending on the study)4–6.
It is likely that multiple B. fragilis strains can coexist in the GI
tract and that competition between these strains is determined by
their adherence and other virulence factors. The pathogenesis of
ETBF is dependent on the secretion of BFT, a zinc-binding
metalloprotease7–9. B. fragilis with a deleted bft gene is unable to
cause inflammation in mouse colitis models9. Three different BFT
isoforms have been identified and named as BFT-1, BFT-2, and
BFT-310, whose encoded amino acid sequences are >93%
identical10,11. Thus, BFT production and activity might depend
on the B. fragilis strain and secreted BFT isotype in vivo. While
bft expression can be inhibited by glucose and fermentable car-
bohydrates present in the GI tract, oxygen and the cysteine
protease fragipain (Fpn) present in high concentrations in the
mucus layer upregulate bft expression potentially enabling suc-
cessful colonization in the gut mucosa12,13.
On the mucosa, BFT directly interacts with colonic epithelial
cells (CECs) triggering cell morphology changes14, actin
rearrangement15, E-cadherin degradation16–18, as well as activa-
tion of a spectrum of cellular signaling pathways, including NF-
kB (resulting in IL-8 secretion)19, ERK/P38 MAPKs, and Wnt/
beta-catenin pathways corresponding with increased CEC
expression of c-Myc9,16–18,20. Consistent with the capacity of BFT
to diminish colon barrier function, mice colonized (by oral
gavage) with ETBF develop acute IL-17-dominant colitis followed
by protracted (~1 year) ongoing colonization, chronic colon
inflammation, and persistent excess mucosal IL-1721,22. Impor-
tantly, ETBF colonization of multiple intestinal neoplasia mice
(Apc+/Min), a Wnt-signaling mouse tumorigenesis model, induces
IL-17- and NF-kB-dependent distal colon tumor
formation9,23–25. These observations combined with human
research data1–3,26,27 suggest that ETBF colonization may be a
risk factor for human colon carcinogenesis. Further, our recent
report suggests that ETBF may act synergistically with another
oncogenic bacterium, polyketide synthase-positive Escherichia
coli (pks+ E. coli) to initiate tumor formation in patients with the
familial adenomatous polyposis (FAP) syndrome28. However,
many fundamental questions remain regarding how CECs sense
environmental changes and interact with BFT to maintain
homeostasis or promote disease upon ETBF colonization.
Recently, several reports have suggested that the G protein-
coupled receptor (GPR)35 may be related to gastrointestinal
inflammation and colitis. In 2009, a GWAS for early-onset IBD
linked a single-nucleotide polymorphism (SNP) in GPR35
(rs4676410) to ulcerative colitis29. Later, a second GWAS study
showed that a missense SNP within GPR35 (rs3749171) was
associated with both primary sclerosing cholangitis (PSC) and
ulcerative colitis30. More recently, another GWAS and immu-
noChip study reported an association between a GPR35 poly-
morphism at 2q37 and Crohn’s disease31. Together, these reports
suggest that GPR35 polymorphisms contribute to the pathogen-
esis of IBD.
GPR35 is an orphan receptor first identified in 1998 by
O’Dowd et al.32. The protein has seven transmembrane regions
and comprises 309 (short isoform) or 340 amino acids (long
isoform). A connection between GPR35 signaling and cell
transformation and/or proliferation has been proposed by Oku-
mura et al. through their initial identification of the long GPR35
isoform (GPR35b)33. To date, five different splice variants have
been described (Ensembl, ENSG00000178623). GPR35 is highly
expressed in the gastrointestinal (GI) tract, from the stomach to
rectum, and enhanced in CRC tissues based on data from the
Human Protein Atlas34. It is predominantly expressed in the
intestinal crypt enterocytes and in several immune cells, such as
invariant natural killer T cells and peripheral blood mononuclear
cells (PBMCs)35,36. Kynurenic acid, a metabolite of L-tryptophan,
has been proposed to be the endogenous ligand of GPR3535.
Upon kynurenic acid-mediated GPR35 activation, β-arrestin 2
translocates to the cell membrane to mediate GPR35 inter-
nalization, resulting in receptor desensitization37. Studies on the
roles of kynurenic acid in immunity and inflammation have
suggested a role for kynurenic acid–GPR35 interactions and
microbiota-associated kynurenic acid metabolism in gut home-
ostasis. Schneditz et al. reported recently that GPR35 promotes
glycolysis, proliferation, and oncogenic signaling by engaging
with the sodium potassium pump in CECs38. This knowledge
suggests that GPR35 could play an important role in
host–microbiome interactions.
In this study, we identified GPR35 as crucial to BFT action
in vitro and then extended these results using in vivo mouse
models to test the hypothesis that GPR35 expressed on the CEC
membrane senses and reacts to BFT. We demonstrate that GPR35
is an important regulator of the early response to ETBF infection.
Results
Identification of GPR35 as a signaling molecule for BFT. In an
attempt to identify essential CEC molecules mediating the initial
cellular interaction with BFT, a microarray data subtraction
comparison among the BFT-responsive CRC epithelial cell lines
HT29/c1 (in this study), HT29 (GSM396550), T84 (in this study),
Caco-2 (GSM24832), and SW480 (in this study) versus the BFT
nonresponsive kidney cell line HEK293 (in this study) and HeLa
cells (GSM410912) was conducted. The total RNA was extracted
using Direct-zol RNA kit (ZYMO research) from cultured cells,
and the microarray was performed using Human transcriptome
array 2.0 (Affymetrix) by the JHMI Deep Sequencing & Micro-
array Core facility. We identified 82 epithelial membrane-related
proteins as potential receptor candidates in BFT-responsive cells
(Supplementary Data 1). We used lentiviral shRNA knockdown
(KD) screening of these 82 proteins to identify candidate proteins
that diminished or blocked the morphological changes in HT29/
c1 cells (details on shRNA infection below) induced by BFT
treatment (5 nM) for 3 and 24 h. Based on this initial screening,
three clones emerged as they showed reduced morphological
change [c1–8 (GPR35, TRCN0000008887), c6–9 (Claudin-4,
TRCN0000116627), and c3–7 (RAB20, TRCN0000048093)]
(Supplementary Table 1). These three clones and the membrane
receptor CD44 (TRCN0000057563) as control were selected to
generate stable cell lines. Morphology assay and E-cadherin
western blot were performed with and without BFT for 1–3 h to
confirm the loss of BFT activity in these stable cell line clones.
The stable KD clone 1–8 targeting the 3UTR region of GPR35
(GPR35 mRNA reduced to 79% of untreated control, N= 3, P <
0.01, Fig. 1a) showed a nearly complete inhibition of BFT
biological activity based on morphology change (Fig. 1b), reduced
IL-8 secretion (Fig. 1c), and reduced E-cadherin cleavage
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compared to the vector control by both immunofluorescence and
western blot (Fig. 1d, Supplementary Figs. 1a and 5b). None of
the other shRNA clones, targeting Claudin-4, CD44, and RAB20,
inhibited E-cadherin cleavage by BFT (Supplementary Figs. 1a
and 5b). Thus, out of these four proteins, only GPR35 emerged as
a candidate for BFT signaling on the CEC membrane.
Next, we generated additional stable GPR35 shRNA KD clones
from HT29/c1 cells infected with 6 different shRNA lentiviral
constructs (see “Methods”). GPR35 mRNA was significantly
reduced in two construct-infected cells named clone 1 (−71.3%,
N= 5, P < 0.01), and clone 2 (−33.4%, N= 5, P < 0.01); no other
clones demonstrated GPR35 KD (clones 3–6, N= 2 each, Fig. 1a).
Therefore, we further evaluated both clone 1 and clone 2. While
the original clone 1–8 almost completely blocked BFT-induced
morphological change (Fig. 1b), the newer GPR35 KD clones 1
and 2 revealed only a modest reduction in BFT-induced HT29/c1
cell morphology changes (clone 1, no effect; clone 2, 25.5%
reduced cell morphology score, N= 4, P < 0.05) (Fig. 1b) and no
blockade of E-cadherin cleavage. When analyzing downstream
IL-8 signaling, all GPR35 KDs (clones 1–8, clones 1 and 2)
displayed a similar decrease in IL-8 protein secretion (2.17 ± 0.04
(clone 1–8), 2.41 ± 0.23 (clone 1), 1.95 ± 0.35 (clone 2), vs 4.04 ±
0.27 (wild type), N= 3, P < 0.01, Fig. 1c). Collectively, our shRNA
KD results suggest a role for GPR35 in BFT signaling although
this likely depends on the level of KD and/or the remaining
protein function and expression. Because high-affinity, specific
GPR35 antibodies are currently unavailable, we had to rely on
mRNA to analyze GPR35 expression levels without the ability to
accurately assess protein levels. We further note that even in clone
1–8 that displayed the highest KD-level and the corresponding
downstream effects, cell response following BFT treatment was
only temporarily delayed (~3 h) but not completely blocked by
the GPR35 KD.
GPR35 expression in CEC lines correlates with cell sensitivity
to BFT. To further evaluate the relationship between GPR35
expression and the cell response to BFT, we investigated the mRNA
level of GPR35 isoform a (GPR35a, 309 amino acids) and isoform b
(GPR35b, 340 amino acids) in several CEC lines. The long isoform
(GPR35b) has 31 extra amino acids at the N-terminal site of the
protein (Supplementary Fig. 1b). Our results suggest that GPR35b is
the dominant isoform present in the colon carcinoma cell lines
examined, matching data in public databases (Supplementary
Fig. 1c). When normalized to GAPDH expression, HT29/c1 cells
have the highest mRNA level of GPR35 followed by Caco-2 cells,
whereas HCT116 cells showed the lowest GPR35 expression levels.
Consistent with these data, HCT116 cells display limited cell
morphologic changes and E-cadherin cleavage after BFT treatment
when compared to HT29/c1 cells. As an additional assessment, IL-8
expression after BFT treatment was more pronounced in HT29/c1
Fig. 1 Clone 1–8 GPR35 KD by shRNA results in reduced morphology change, E-cadherin cleavage, and IL-8 secretion. a GPR35 mRNA expression levels
relative to GAPDH. GPR35 expression is significantly reduced compared to wild-type (WT) HT29/c1 cells (N= 8) in the GPR35 shRNA clones 1–8 (N= 5,
P < 0.01), 1 (N= 5, P < 0.01), and 2 (N= 5, P < 0.01), but not in clones 3, 4, 5, and 6 (N= 2 each, one-sample T test). Dashed line represents WT GPR35
level. Two points of clone 4 (540 and 947%) outside the y axis. b Morphology changes of HT29/c1 cells were reduced by clone 1–8 (N= 3, P < 0.05), and
clone 2 (N= 4, P < 0.05), but not clone 1. Dashed line represents WT toxin score (100%). c IL-8 secretion was significantly reduced in all three
GPR35 shRNA clones (clone 1–8, clone 1, and clone 2) (N= 3, P < 0.01) compared to HT29/c1 WT cells (N= 6). d Representative pictures of morphology
(top panels) and intact E-cadherin (green, bottom panels). Untreated HT29/c1 WT and GPR35 shRNA clone 1–8 cells are shown in (a) and (c),
respectively. After 3 h, BFT changed morphology and cleaved E-cadherin in WT cells (b), but not in the GPR35 shRNA clone 1–8 cells (d).
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than in HCT116 cells (Supplementary Fig. 1d; 9.46-fold and 3.34-
fold, respectively, P <0.01, N= 2). These data suggest a correlation
between the level of GPR35 expression and cell sensitivity to BFT.
BFT signaling is inhibited by the selective GPR35 antagonist
ML145. The chemical antagonist of GPR35, ML145, has been
shown to specifically inhibit GPR35 signaling by the known
agonists Zaprinast (PubChem CID 135399235) and compound 10
(PubChem CID 2295463)39,40. ML145 has a high affinity for
human GPR35 and, for example, has a >1000-fold higher affinity
toward GPR35 than GPR55; ML145 is the most selective known
antagonist for GPR3541. To further investigate whether GPR35 is
involved in BFT signaling, we pretreated HT29/c1 cells (30 min)
with 20 µM ML145 followed by incubation with BFT to deter-
mine morphological changes, E-cadherin cleavage, and IL-8
secretion. BFT-induced morphological changes were significantly
reduced for up to 3 h by treatment with the inhibitor ML145
(1.92 ± 1.01, cell morphology score, see “Methods”) when com-
pared to treatment with BFT alone (3.17 ± 0.14 two-way ANOVA
P= 0.023 (1 h) and P= 0.015 (3 h) N= 3) (Fig. 2a, b). Reduced
cell morphological change by ML145 correlated with a decrease in
the release of the 80-kDa extracellular domain of E-cadherin from
HT29/c1 cells when compared to cells treated with BFT alone
(3.2-fold vs 12.2-fold (P < 0.01, N= 3), respectively) (Fig. 2c). IL-
8 secretion by HT29/c1 cells induced upon BFT treatment was
also inhibited by ML145 at 20 µM (139.5 pg/ml ML145+BFT vs
302.5 ng/ml BFT alone, P < 0.05, N= 3, Fig. 2d). Together, these
data further support a role for GPR35 in facilitating BFT-induced
HT29/c1 cell morphologic changes, E-cadherin release, as well as
increased secretion of IL-8.
BFT stimulates β-arrestin recruitment in HT29/c1 cells sup-
porting GPCR involvement. G protein-coupled receptor (GPCR)
signaling involves the recruitment of beta-arrestins (β-arr) to
desensitize and internalize GPCRs42. Recent research indicates
that β-arrs can also function as signal transducers for GPCRs and
result in activation of MAPK and ERK pathways via interaction
with Src family kinases43. For GPR35, β-arr2 is considered the
most substantially involved in response to agonists44. To evaluate
whether GPCR signaling is involved in the cellular response to
BFT, β-arr recruitment was measured in HT29/c1 cells exposed to
BFT or compound 10, a known GPR35 agonist. HT29/c1 cells
stimulated with BFT had an increased intracellular β-arr2 signal
measured at 30 and 60 min (P < 0.001, N= 6) similar to the
positive control (GPR35 agonist compound 10) (Fig. 3a, b). We
noted that BFT stimulation for 4 h (240 min) increased the β-arr1
and β-arr2 signal in the membrane-associated region when
compared to nonstimulated cells (Supplementary Fig. 2a; N= 3).
An increased perinuclear staining was also noted for β-arr2 fol-
lowing BFT treatment. Analysis of cytoplasmic and membrane-
associated proteins from HT29/c1 cells stimulated with BFT for 4
h using western blotting confirmed increased membrane-
associated signals for both β-arr1 and β-arr2 (Supplementary
Fig. 2b, Supplementary Fig. 5c–f). Together, these experiments
indicate that exposure of HT29/c1 cells to BFT activates β-arr1
and β-arr2 signaling consistent with our hypothesis that BFT
induces GPR35 signaling.
Stable KD clones of β-arr1 and β-arr2 were generated using
lentiviral shRNA in HT29/c1 cells to determine whether the
presence of β-arr1 and/or β-arr2 is required for BFT-stimulated
GPCR signaling (Supplementary Fig. 2c). BFT stimulation of the
β-arr1 and β-arr2 KD clones had no effect on morphology
Fig. 2 The GPR35 antagonist ML145 inhibits CEC response to BFT in HT29/c1 cells. HT29/c1 cells were treated for 1 h (a) and 3 h (b) with BFT and
increasing concentrations of the GPR35 antagonist ML145 (N= 3). Treatment with ML145 significantly inhibited changes in HT29/c1 cell morphology
(two-way ANOVA P= 0.023 and P= 0.015, 1h (a) and 3 h (b), respectively) compared to the positive control (BFT without antagonist—dotted lines).
Treatment with 2 and 20 µM of ML145 inhibited BFT morphological changes at 1h and 20 µM ML145 at 3 h (Dunnet’s multiple comparison test *P < 0.05,
**P < 0.01, ***P < 0.001). c BFT treatment significantly enhanced the release of E-cadherin into the culture supernatant (P < 0.001). E-cadherin release was
significantly inhibited by ML145 (N= 3, P < 0.01). d BFT treatment significantly enhanced IL-8 secretion into the culture supernatant (P < 0.01). IL-8
secretion was significantly inhibited by ML145 (N= 3, P < 0.05; two-way ANOVA with Bonferroni post test in c and d).
ARTICLE COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-021-02014-3
4 COMMUNICATIONS BIOLOGY |           (2021) 4:585 | https://doi.org/10.1038/s42003-021-02014-3 | www.nature.com/commsbio
change, demonstrating that β-arr1 and β-arr2 are not required for
BFT changes in cellular shape. Rather, the BFT-induced release of
the extracellular domain of E-cadherin was enhanced in the stable
β-arr KD clones when compared to control cells (6.63-fold
increased release wild type, 16.6-fold β-arr1 KD and 13.9-fold β-
arr2 KD, N= 1) (Fig. 3c), while IL-8 secretion was similarly
induced in wild-type and KD cells following 4 h of BFT
stimulation (2.41-fold increase wild type (N= 3), 2.43-fold β-
arr1 KD (N= 3), and 2.03-fold β-arr2 KD (N= 3); one-way
ANOVA P= 0.64). β-arr1 and β-arr2 KD also resulted in a
significant baseline increase (P < 0.001) in IL-8 secretion (Fig. 3d).
The observed enhancement of CEC E-cadherin release and IL-8
secretion following BFT treatment in the β-arr1 and β-arr2 KD
cells supports the desensitizing role played by β-arrestins
following BFT treatment.
CRISPRcas GPR35 KO in HT29/c1 cells also results in delayed
BFT response. To further confirm the function of GPR35 during
the CEC response to BFT stimulation, we generated three
sequence-confirmed GPR35 KO clones in HT29/c1 cells with the
CRISPRcas system using four guide RNAs (gRNAs) located on
the first extracellular and transmembrane domains (amino acids
10–43) of GPR35a. Clone 2AH5 resulted in 39% frameshift
deletions ranging from 4 to 29 bp that result in alternative protein
coding around Tyr 26, and 3% resulted in in-frame deletions
removing Val 32 (3 bp) or Leu 31-Leu 39 (21 bp) that retained
high similarity to wild-type GPR35 protein (Supplementary
Fig. 3a, b). Clone 2BE5 showed an 8-bp GPR35 deletion (36%)
that resulted in a frameshift translation starting at Leu 40
(GPR35a); however, 32% of the sequences resulted in an in-frame
deletion of 9bp, resulting in deletion of 3 amino acids at Leu 40
(19%) or Asn 38 (13%) while again retaining high similarity to
the wild-type GPR35 protein. In clone 2AA9, only heterogenous
deletions were observed consisting of 6% in-frame and 6% fra-
meshift deletions at Tyr 26 ranging from 9 to 28 bp (Supple-
mentary Fig. 3a, b). Protein alignment using CLUSTALW Omega
and a phylogenetic tree based on a point mutation matrix (PAM)
of the suggested protein translations of the GPR35 KO clones
showed high similarity between KO 2AA9, 2BE5, and wild-type
GPR35, but not 2AH5 (Supplementary Fig. 3a, b).
Real-time PCR that amplified codon regions Ile (156) to Ala
(185) showed that GPR35 mRNA was reduced 49% for clone
2AH5 (N= 4, P < 0.05), 79% for clone 2AA9 (N= 4, P < 0.01),
and 48% for clone 2BE5 (N= 2, NS) compared to wild-type
HT29/c1 cells (Fig. 4a). Only clone 2AH5 displayed a significant
decrease in HT29/c1 cell morphology change after BFT treatment
(decrease 92.2% for 2AH5 (N= 4, P < 0.01), while clone
2BE5 showed a heterogeneous decrease in cell morphology
change (39.2%, N= 4, NS) and no change was observed for clone
2AA9 (N= 4, NS) (Fig. 4b, c)). This corresponded with a
reduction in E-cadherin cleavage of 22.4% for clone 2AH5
compared to the BFT control, but little (7.5% decrease) to no
impact on E-cadherin cleavage for clone 2AA9 and clone 2BE5,
respectively (Fig. 4d and Supplementary Fig. 5a). IL-8 secretion
was reduced only in clone 2AH5 (N= 2, P < 0.05), but was not
changed in 2BE5 (N= 2, NS), while clone 2AA9 showed
significantly increased levels of IL-8 (N= 2, P < 0.05) (Fig. 4e).
Although the previous experiments suggested a reduced
expression of GPR35 for clones 2AA9 and 2BE5 (Fig. 4a), no
Fig. 3 β-arrestin signaling following BFT treatment. a The β-arr2 signal in HT29/c1 cells was increased after 30 and 60min of treatment with BFT to
levels similar to that of cells treated with the GPR35 agonist compound 10 (P < 0.001, N= 6). Representative images of β-arr2 staining are shown in (b) at
×400 magnification. c E-cadherin cleavage with the release of the E-cadherin extracellular domain was enhanced in β-arr1 and −2 KD cells after both 30
and 60min of BFT treatment compared to control BFT-treated HT29/c1 cells (N= 1). d Baseline IL-8 secretion was increased in β-arr1 and −2 KD cells
compared to control cells (P < 0.001, N= 2 each). While IL-8 secretion after BFT treatment was increased in the β-arr1 and β-arr2 KD (P < 0.001), the
overall fold change in IL-8 secretion (BFT vs nontreated ctrl) was similar in β-arr1 amd β-arr2 KD cells compared to control cells.
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significant alterations in morphological change, E-cadherin
cleavage, and/or IL-8 secretion were detected, suggesting that
BFT signaling was maintained in these clones, either due to their
high similarity to wild-type GPR35 resulting from the in-frame
deletion (2BE5) or because of a low percentage of mutant DNA in
the sample (2AA9). It is likely that the high similarity in sequence
between the clones 2AA9, 2BE5, and wild-type GPR35 resulted in
the preservation of BFT signaling. This is in contrast to the
reduced BFT-dependent signaling observed in clone 2AH5.
Importantly, both CRISPRcas clone 2AH5 and shRNA clone
1–8 only yielded a short-term delay in the CEC response to BFT,
suggesting that while GPR35 contributes to BFT signal transduc-
tion, inhibition of this pathway alone is insufficient to abrogate
CEC responsiveness to BFT.
To further investigate the role of GPR35 in CECs, enteroids
derived from the colons of wild-type -C57Bl6 and GPR35−/−
(KO) mice were exposed to BFT (25 nM) for 3 h. GPR35−/−
enteroids also showed a delayed morphological change following
BFT treatment when compared to wild-type -C57Bl6 enteroids
(N= 3, Fig. 4e). The ex vivo enteroid data recapitulate the delayed
responsiveness to BFT observed with ML145 GPR35 inhibition,
shRNA KD (clone 1–8), and KO by CRISPRcas (clone 2AH5).
Together, these data suggest that colon CEC GPR35 functions, in
part, as a signaling molecule for the CEC response to BFT, but
loss of GPR35 is insufficient to prevent in vitro BFT–CEC activity
and signaling.
GPR35 does not facilitate BFT binding to the intestinal epi-
thelial cells. These in vitro results point toward an important role
for GPR35 in BFT-induced cellular signaling. In previous
research, we have shown that BFT interacts with an epithelial cell
receptor on colon HT29/c1 cells20. To investigate whether GPR35
is a binding partner for BFT, recombinant BFT labeled with Alexa
488 was visualized using confocal microscopy in HT29/c1 wild-
type cells and shRNA KD clones 1–8, 1 and 2. Although mor-
phological change was significantly reduced in clone 1–8, BFT
bound similarly on the epithelial cell surface of all KD clones and
Fig. 4 GPR35 knockout in HT29/c1 cells and mouse organoids results in delayed BFT response. a CRISPRcas KO of GPR35 in three confirmed clones
2AH5, 2AA9, and 2BE5 resulted in reduced GPR35 mRNA expression levels for 2AH5 (N= 4, P < 0.05) and 2AA9 (N= 4, P < 0.01) but not for 2BE5 (N=
2). b, c Morphology changes following BFT treatment in CRISPRcas KO were only reduced for clone 2AH5 but not for 2AA9 and 2BE5. d E-cadherin
cleavage, determined through western blotting, was reduced to 72% in 2AH5 compared to 94.5% in WT HT29/c1 cells, but was not totally inhibited. A
representative western blot and corresponding actin controls are depicted (N= 3). e The fold change of IL-8 secretion in BFT-treated versus nontreated
control cells was significantly reduced only for the CRISPRcas KO cell line 2AH5 (N= 2, P < 0.05). f Enteroids derived from the WT and GPR35−/− distal
mice colon exposed to BFT show a delayed change in morphology at 3h after treatment with BFT in the GPR35−/− condition.
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wild-type HT29/c1 cells. In addition, BFT binding was main-
tained in the 2AH5 CRISPRcas clone compared to wild-type
HT29/c1 cells and the KO 2AA9 clone that served as an addi-
tional positive control (Fig. 5a). Next, we visualized biotin-labeled
recombinant BFT at the epithelial cell surface in HT29/c1 wild-
type cells with and without 20 μMML145 antagonist that binds to
GPR35, to further assess the direct binding of BFT to GPR35.
Inhibition with ML145 did not result in a reduced binding of BFT
to the epithelial cells (Fig. 5b). Similarly, doxycycline-induced
overexpression of hGPR35-eYFP in HEK293 cells that do not
respond morphologically to BFT did not result in morphologic
changes upon BFT treatment or enhanced BFT binding to the cell
surface of the HEK293 cells (Fig. 5c). Hence, while we show that
GPR35 is an important interaction partner for BFT, our results do
not suggest that BFT is a direct ligand of GPR35.
GPR35 deficiency decreases the lethal reaction of mice to ETBF
infection. We next evaluated the contribution of GPR35 to the
pathogenesis of ETBF in vivo using two mouse colitis models
pretreated with antibiotics. Pretreatment with oral clindamycin/
streptomycin (clin/strep) facilitates ETBF colonization in mice. In
the clin/strep model, mice generally survive ETBF colonization
and the severity of the colitis wanes after 5–7 days post- coloni-
zation but occasional mouse death occurs. In contrast, pretreat-
ment with oral cefoxitin, a broad-spectrum antibiotic, increases
the severity of ETBF colitis and can cause high mortality during
the acute phase of ETBF colitis, likely due to the near-complete
elimination of the murine microbiota45. Herein, given our in vitro
results on the early contribution of GPR35 in BFT signaling, we
focused on the evaluation of the early phase of ETBF colitis. First,
in an experiment with severe colitis in clin/strep pretreated mice,
ETBF colonization resulted in the death of 5/6 wild-type (GPR35
+/+) mice, while none of the GPR35−/− mice died in the same
experiment after ETBF colonization (n= 6 each, P= 0.0186, log-
rank test) (Fig. 6a). In the cefoxitin-pretreated ETBF-colonized
mice, 7 of 15 wild-type GPR35+/+ mice (46.67%) and 12 of 27
GPR35+/− mice (44.44%) died within 7 days of ETBF coloniza-
tion, whereas only 1 of 25 GPR35−/− mice died (4.0%) (n= 3
experiments, P= 0.0367 log-rank test) (Fig. 6b). Clinically,
cefoxitin-pretreated GPR35−/− mice appeared less ill and gained
body weight similarly to sham mice (P= 0.5904), differing from
ETBF-colonized GPR35+/− or wild-type GPR35+/+ mice that
Fig. 5 GPR35 does not facilitate BFT binding to CECs. a HT29/c1 WT, GPR35 KO 2AH5, and GPR35 KO 2AA9 cells incubated with alexa488-labeled BFT.
Blocking of 488-labeled binding with non-labeled BFT was used to show the specificity of the BFT–CEC binding. Images at ×600 magnification. b Binding of
concentration series of biotin-labeled recombinant BFT to HT29/c1 epithelial cells and cells treated with 20 μMML145 (NS). c BFT binding to HEK293 cells
noninduced or induced to express human GPR35-eYFP. The nucleus is stained with DAPI (blue), BFT (red), and GPR35-eYFP (green). Images at ×400
magnification.
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showed significant body weight loss (P= 0.0452 and 0.0158,
respectively, Fig. 6c, right panel). A similar but less pronounced
body weight change was observed in ETBF-colonized clin/strep-
treated mice (Fig. 6c, left panel). Analysis of cytokine expression
by qPCR 3 days after ETBF colonization revealed limited differ-
ences between GPR35−/− and wild-type GPR35+/+ mice in the
distal colon. Notably, expression of Il17a, a signature inflamma-
tory cytokine for ETBF infection, and Nos2, a general
inflammation marker, did not differ (Fig. 6d). However, mRNA
expression of Il-22 (important for host defense and mucosa
regeneration), Cxcl5 (also known as epithelial-derived neutrophil-
activating peptide 78 (ENA-78)), and metallothionein (Mt2) (a
modulator of the immune response by zinc sequestration) were
significantly reduced in GPR35−/− mice when compared to wild-
type-infected ETBF mice. Histologically, the GPR35+/+ mice that
survived 3 days of ETBF infection showed mucosal damage,
Fig. 6 GPR35-knockout mice show reduced lethality and less severe colitis after ETBF colonization. a Percentage survival of clin/strep pretreated
GPR35+/+ (WT) and GPR35−/− mice in a severe colitis experiment 3 days post ETBF infection (P= 0.0186) (N= 6 each). b Percentage survival of
cefoxitin-treated GPR35+/+ (WT) (N= 22), GPR35+/− (N= 39), and GPR35−/− (N= 26) mice over 7 days post ETBF colonization (P= 0.0367). c
Mouse body weight change in cefoxitin and clin/strep-treated mice. Body weights of GPR35+/+ (WT), GPR35+/−, and GPR35−/− mice were compared
3 days after ETBF colonization to their own baseline (day 0). Sham (N= 6 and N= 4), GPR35+/+ ETBF (N= 9 and N= 7), GPR35+/− ETBF (N= 22 and
N= 15), and GPR35+/− ETBF (N= 7 and N= 6) for Clin/Strep and Cefoxitin models, respectively. d) Il17a, Nos2, Il22, Cxcl5, Il6, Ifn-γ, Tnf-α, Mt1, and Mt2
expression in the distal colon of GPR35+/+ and GPR35−/− ETBF-colonized mice compared to their sham controls at 3 days post colonization. Significant
differences were observed for Il22, Cxcl5, and Mt2. Individual mice are represented in each dot. e H&E-stained sections of mouse distal colons from clin/
strep pretreated GPR35+/+ and GPR35−/− mice at 3 days post ETBF colonization compared to the sham. Mild and severe ETBF colitis histology are
shown in GPR35+/+ mice with corresponding GPR35−/− mice.
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including bleeding, epithelial cell shedding, and ulcerations.
Overall, there was neither a clear difference in lamina propria
immune cell infiltration, number of ulcerations, and lymphocyte
aggregates between GPR35−/− and GPR35+/+ mice that survived
after ETBF colonization (Fig. 6e) nor a difference in E-cadherin
detection (Supplementary Fig. 4). However, CEC shedding in
severe ETBF colitis in GPR35+/+ mice exceeded that observed in
ETBF-colonized GPR35−/− mice (Fig. 6e, lower panel). Alto-
gether, these results revealed decreased overall mortality, and
decreased colitis-induced weight loss, and suggest that GPR35
contributes, at least, in part to early ETBF-induced colon
inflammation. These in vivo results add to our in vitro results
indicating that GPR35 mediates, in part, the early signaling
response to BFT, and has an early impact on ETBF colitis.
Discussion
In this study, we show that GPR35 plays an important role in the
CEC response to BFT produced by ETBF (Fig. 7). Our in vitro
results indicate that blocking GPR35 activity using selective
antagonists of GPR35, shRNA knockdown, and CRISPRcas
knockout contributes to a delayed CEC response to BFT. In
addition, our ex vivo results using colon enteroids of GPR35-
knockout mice confirm that GPR35 is important for sensing BFT
in CECs. In two mouse models of ETBF colitis, GPR35 knockout
resulted in less body weight loss, less severe colitis, and an
increased survival rate at 3–7 days post ETBF colonization,
despite no decrease in Il17a expression, a key mediator of ETBF
colitis9. Together, these results indicate that GPR35 plays an
important role in the early CEC and mucosal response to BFT
in vitro and in vivo.
HT29/c1 cells, the subclone of the human CRC cell line HT29,
are highly sensitive to BFT and have been previously used as an
in vitro model to study BFT–CEC interactions14. In addition,
HT29 cells have been used as a model to screen for chemical
agonists of GPR3546,47. In this study, we verified GPR35
expression in HT29/c1 cells38 and showed a correspondence of
GPR35 expression with the level of BFT-induced E-cadherin
cleavage and IL-8 secretion in CECs. BFT treatment of HT29/
c1 cells resulted in βarr1 and βarr2 recruitment, indicating acti-
vation of GPCR signaling by BFT. Cellular knockdown of βarr1
and βarr2 resulted in enhanced BFT-induced E-cadherin cleavage
and IL-8 secretion, indicating that beta-arrestin recruitment is
most likely involved in internalization and desensitization of
GPR35, limiting to some extent BFT action48. For some GPCRs
the β-arr-mediated signaling relies on either β-arr1 or β-arr2, and
is inhibited by the other respective βarr forms (reciprocal reg-
ulation). Alternatively, GPCR signaling can also depend on both
βarrs49. Our data suggest thatboth βarrs are activated upon BFT
treatment of CECs.
Inhibition of GPR35 function using the selective antagonist
ML145 reduced BFT-mediated changes in cellular morphology
and downstream effects following BFT exposure. BFT causes
actin cytoskeleton rearrangements in HT29/c1 cells similar to
what occurs following exposure to the GPR35 agonists pamoic
acid and zaprinast in human saphenous vein cells50. This mor-
phological change in saphenous vein cells by GPR35 agonists was
also inhibited with the GPR35 antagonist ML145 in line with the
inhibition of BFT action15,50. Furthermore, a recent study
investigating the signaling network of GPR35 in HT29 cells shows
that stimulation of GPR35 with agonists pamoic acid and YE210
is related to changes in morphological processes, such as cytos-
keletal remodeling and has a function in inflammation47, both of
which are also affected by BFT. When GPR35 mRNA was
inhibited by shRNA (clone 1–8), and functionally knocked out by
CRISPRcas (clone 2AH5), HT29/c1 cells displayed a significant
delay in BFT response. Unfortunately, we were unable to find a
functional GPR35 antibody for verification of GPR35 expression
at the protein level after knockdown and knockout, and we had to
rely on mRNA expression patterns and in silico modeling of
GPR35 protein knockout. The latter suggested that the 2AH5-
knockout clone resulted in a frameshift deletion and a different
protein composition matching our functional BFT activation
experiments. The KD and KO results were confirmed in GPR35-
knockout mouse enteroids that demonstrated a delayed reaction
to BFT, but the response was not completely eliminated. Toge-
ther, our data show that blocking GPR35 impairs but does not
eliminate the biological activity of BFT.
So far, there is no evidence for the direct interaction of BFT
with GPR35. In our previous work, we showed that BFT binds an
unknown receptor that triggers γ-secretase activation, resulting in
canonical E-cadherin cleavage18. Specific binding of BFT requires
BFT protease activity20. Here, we show that GPR35 senses BFT,
and is involved in the downstream actions of BFT, but the
binding of BFT to the epithelial cell is maintained in GPR35
knockdown and knockout cells as well as cells treated with the
selective GPR35 antagonist ML145, indicating that BFT binding
is not mediated by GPR35. In addition, the overexpression of
GPR35 in BFT-unresponsive HEK293 cells did not result in
increased BFT binding. This points toward a more complex
interaction between GPR35 and BFT at the epithelial cell mem-
brane. We hypothesize that ETBF/BFT can trigger the activation
of GPR35 signaling through a ligand-dependent and/or -inde-
pendent mechanism. For example, BFT could trigger the
Fig. 7 Graphical abstract. Graphical abstract summarizing the in vitro and
in vivo findings on enterotoxigenic Bacteroides fragilis (ETBF) toxin (BFT)
and epithelial cell signaling through GPR35. In the top panel, the in vitro
findings with GPR35 shRNA knockdown (KD), inhibition with GPR35
antagonist ML145, and CRISPRCas knockout (KO) on morphological
change, E-cadherin cleavage, and IL-8 secretion upon stimulation of HT29/
c1 cells with Bactetoides fragilis toxin (BFT). In the bottom panel, the in vivo
findings in C57Bl6 wild-type (WT) and GPR35−/− mice pretreated with
cefoxitin antibiotics on body weight change and survival after colonization
with ETBF. *Created with BioRender.com.
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epithelial cell to release a molecule that serves as a GPR35 ligand
to activate GPR35, or GPR35 may be activated under a non-
canonical mechanism. Since GPCRs can interact with cytoskele-
ton and adhesion proteins and BFT can also alter these cellular
components15, this could potentially mediate indirect activation
of GPR35. Nevertheless, GPR35 functions downstream of the
cellular events following BFT exposure and controls the flow of
signaling cascades activated by BFT-receptor interaction.
Importantly, activation of GPR35 leads to cellular responses to
stress and cell morphogenesis47, similar to BFT, showing that
although binding of BFT is not mediated by GPR35, the signaling
networks of BFT and GPR35 at least partly overlap. How
GPR35 senses BFT is an important question to further
investigate.
The data generated from the ETBF mouse colitis models
support our in vitro and ex vivo findings. On day 3 post ETBF
colonization, GPR35-knockout mice showed improved clinical
responses and survival in two mouse models. The reduced death
rate and increased body weights in GPR35-knockout mice com-
pared to wild-type mice suggest that CECs are less responsive to
BFT in the absence of GPR35. Altogether, this supports the
notion that GPR35 is important in the initial epithelial response
to ETBF/BFT in the mouse colon. The only genes that were
differentially expressed in GPR35−/− compared to wild-type mice
following ETBF infection were Cxcl5, Il-22, and Mt2. These are all
important genes in the innate immune response, as
CXCL5 stimulates neutrophil recruitment51, IL-22 is important
for host defense and mucosa regeneration52, and metallothionein
MT2 functions as a modulator of the immune response by zinc
sequestration, a metal important for the function of immune
cells53. As downregulation of MT2 also results in a reduced
availability of extracellular zinc pools, this may affect the function
of cellular metalloproteinases and BFT as well, since BFT is a
zinc-dependent metalloprotease54. We have previously shown
that ETBF induces NF-kB activation and Cxcl5 expression, pri-
marily in the distal colon CECs9. These CEC actions of BFT
trigger the accumulation of myeloid cells in the distal colon and
the onset of the mucosal IL17A response to ETBF, both of which
contribute to ETBF procarcinogenesis9,23,55. Thus, a full response
to ETBF colonization requires the participation of both CECs and
the mucosal immune response. Herein, our use of both in vitro
and in vivo models allowed us to partially dissect the contribu-
tions of GPR35 in CECs and the mucosal immune response to
ETBF. Both our in vitro and in vivo GPR35−/− models were
consistent in showing biologic delays in the response to BFT
(in vitro) or ETBF (in vivo). Additional studies will be needed to
more definitively determine the contribution of GPR35 in dif-
ferent cell types to ETBF colonization and signaling. Because our
model involves global KO of GPR35 and the literature indicates
that GPR35 is important in CEC biology and may play an
important role in gut macrophages, additional work is needed to
discern the contributions of GPR35 in the CEC and/or immune
cell compartments to ETBF pathogenesis56,57.
Multiple factors could explain why only a reduction in
inflammation was observed in GPR35−/− mice compared to
wild-type mice at the initial stage of ETBF infection. The gut
microbial ecosystem is complex and multiple factors may con-
tribute to the inflammatory response upon ETBF infection. For
example, ETBF could be a chaperone of other bacteria in pene-
trating through the mucus layer to get direct contact with epi-
thelial cells. This was shown recently for the oncogenic microbes
ETBF and Escherichia coli producing the genotoxin colibactin,
suggesting that ETBF leads the way for DNA-damaging agents
and other oncogenic or colitigenic microbes by degrading the
mucus layer and stimulating a procarcinogenic Th17 response via
colon epithelial cell signaling9,28. Thus, infection with ETBF could
drive microenvironmental changes that regulate microbe:CEC
interactions via separate GPR35-independent pathways. For
example, reduction in E-cadherin expression results in reduced
barrier function and changes the microenvironment of colon
epithelial cells by creating opportunities for invasion of other gut
(opportunistic) microbes that may comediate a colitis response.
Overall, our results suggest that intestinal GPR35 guides the
mucosal inflammation caused by ETBF and is responsible for
sensing BFT in the mucosa. Because GPR35 is also found on
some immune cells, it is possible that not only GPR35 on CECs is
important for BFT-induced colitis, but GPR35 may also be
involved in the interplay between the immune system and CECs
following ETBF colonization.
Our results show that GPR35 is an important signaling
molecule for mediating the CEC and inflammatory effects to
BFT/ETBF. GPR35 polymorphisms on chromosome 2q37 have
been found with GWAS in relation to ulcerative colitis30,58 and
Crohn’s disease31. Importantly, the rs3749171 single-nucleotide
polymorphism results in a T108M mutation of the GPR35 pro-
tein, which has been shown to not only predispose individuals to
ulcerative colitis and PSC but also to cancer risk associated with
these disaeses38. It is therefore necessary to understand the role of
GPR35 polymorphisms in BFT/ETBF signaling. These poly-
morphisms might render certain patients more susceptible to
oncogenic signaling triggered by BFT/ETBF. GPR35 seems likely
to be of importance for other (microbial) signaling molecules and
may play a more general role in bacterial sensing and outcomes in
the colon of patients with IBD.
Methods
Human cell culture. HT29/c1 cells (obtained from Daniel Louvard, Institute
Pasteur) were maintained in DMEM medium supplemented with 10% fetal calf
serum (Gibco), 10 µg/ml apo-transferrin (Sigma T1147), 50 units/ml penicillin, and
50 µg/ml streptomycin (Gibco). Cells were subcultured every 3–5 days for a
maximum of 20 passages.
HEK293T cells (Flp-In T-Rex 293 cells) were stably transfected with FLAG-
HumanGPR35-eYFP cDNA (provided by Graeme Milligan). The construct was
placed into the pcDNA5/FRT/TO vector and the pOG44 vector (1:9) to inducibly
express GPR35 via lentiviral cell infection. Stably transfected cells were maintained
in 10% FCS, 10 µg/ml blasticidin, 200 µg/ml hygromycin B, 50 units/ml penicillin,
and 50 µg/ml streptomycin (Gibco). GPR35 expression was induced with 100 ng/
ml doxycycline for 24–48 h (effective concentration determined by serial dilution).
Bacterial cell culture. Bacteroides fragilis strain O86-5443-2-2 containing the
BFT-2 toxin was grown anaerobically in Brain Heart Infusion (BHI) broth sup-
plemented with 5 g/L yeast extract, 0.5 g/L cysteine, 5 mg/L hemin, and 1 mg/L
vitamin K for 24–48 h for in vitro assays. For mouse inoculation and optimal
colonization, 4–5 colonies were selected from BHI agar and grown for 8 h at 37 °C
in an anaerobic chamber. Bacterial cells were diluted 1:20 in fresh BHI medium
containing 6 μg/ml clindamycin for inoculation. Cells were washed twice with PBS
and resuspended in PBS for inoculation at OD600 of 0.8–1.0.
Toxin assay. The HT29/c1 toxin assay was performed as previously described by
Weikel et al.14 (1992 Infect Immun). In short, HT29/c1 cells were grown until
60–70% confluency on 8-well LabTek slides or 96-well plates. Next, cells were
washed with FCS-free DMEM medium twice before the addition of cell-free
supernatants of BFT-2-producing strain O86-5443-2-2 or purified BFT-2 toxin59 in
concentrations of 100 ng–200 ng/ml in DMEM without FCS. HT29/c1 cells were
exposed to supernatants or purified toxin for 1–3 h. Toxin scoring was performed
by two independent reviewers that were blinded for the conditions.
GPR35 antagonist treatment. The GPR35 antagonists CID2745687 (100 mM)
and ML145 (50 mM) were dissolved in DMSO to create stocks. Concentration
series of ML145 in DMEM were tested on HT29/c1 cells from 20 µM in tenfold
dilutions to 2 nM with a maximum concentration of DMSO of 0.1%. Cells were
pretreated with and without antagonists for 30 min at 37 °C in a humidified
incubator. After 30 min, BFT-2 at 200 ng/ml was added to the wells to reach an end
concentration of 100 ng/ml BFT-2 per well. As a reference for each antagonist
concentration, DMEM without BFT was added. A negative control without toxin
and the highest concentration of DMSO (0.1%) was used. Toxin activity was scored
1 and 3 h after incubation with BFT-2 by three independent persons blinded for
each condition.
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Binding of recombinant BFT to HT29/c1 cells. HT29/c1 cells or HEK293 cells
were seeded in 96-well plates and washed three times with PBS before the addition
of HRP–streptavidin (1:500) to block nonspecific biotin sites on epithelial cells.
Cells were washed and preincubated with ML145 (20 µM) or vehicle (0.1% DMSO)
for 30 min at 37 °C. Next, medium with/without recombinant BFT-1 (rBFT-159)
labeled with biotin at concentrations of 300, 100, 30, 10, 3, and 1 ng/ml was added
to the cells and incubated for another hour at 37 °C. Biotin-labeled BSA was used as
a control to eliminate nonspecific background signal. After incubation, cells were
washed three times with PBS, fixed in 4% paraformaldehyde, and blocked with 5%
BSA–PBS for 1 h at RT. rBFT-1-biotin was visualized with streptavidin-800ICW (1
h RT in 5% BSA–PBS). Cells were counterstained with DRAQ5 (1:2000) for
quantification relative to the cellular density in each well.
shRNA knockdown (KD) with lentiviruses. The initial 82 shRNA clones (shown
in Supplementary Table 1) were provided by the High Throughput Biology Center
(School of Medicine, JHU). The viral particles were packaged in 293T cells using
Mission Lentiviral Packaging Mix (SHP001, Sigma Aldrich). The viral titers were
determined by HIV-1p24 Antigen ELISA (0801111, ZeptoMetrix Corporation).
The additional lentiviral transduction particles were purchased from Sigma Aldrich
as GPR35: clone 1 (TRCN0000357167), clone 2 (TRCN0000357166), clone 3
(TRCN0000367796), clone 4 (TRCN0000008889), clone 5 (TRCN0000008891),
clone 6 (TRCN0000008890), and beta-arrestin: clone β-arr1 (TRCN0000230149)
and β-arr2 (TRCN0000280685). HT29/c1 cells grown on 96-well or 6-well plates
were infected for 18–20 h at 37 °C with 5% CO2 with a multiplicity of infection
(MOI) between 104 and 106 viral particles. The medium was refreshed with DMEM
containing 10% FCS and again incubated for 2–4 days before screening for BFT-
induced morphological change. Stably transfected HT29/c1 cells were selected
using DMEM medium containing 2 mg/ml puromycin.
CRISPRcas GPR35-knockout (KO) HT29/c1 cell line. The GPR35 KO in HT29/
C1 cells using CRISPRcas was performed using a lentiviral delivery system with
four designed guides (1A, 1B, 2A, and 2B). The guides were generated from
genomic DNA of HT29/c1 cells by the following primer set combinations targeting
exon#7 of human GPR35 (2q37.3) [guide 1A: GPR1AF (caccgggggccaggtgaggtcgc)
and GPR1AR (aaacgcgacctcacctggccccc); guide 1B: GPR1BF (caccgtgggcttctacgcc-
tact) and GPR1BR (aaacagtaggcgtagaagcccac); guide 2A: GPR2AF (caccgccagcag-
gacgcccaagt) and GPR2AR (aaacacttgggcgtcctgctggc); guide 2B: GPR2BF
(caccgtcaacagcctggcgctct) and GPR2BR (aaacagagcgccaggctgttgac)]. Each of the
four guide RNAs [1A (gcgacctcacctggcccc), 2A (acttgggcgtcctgctgg), 1B
(tgggcttctacgcctact), and 2B (tcaacagcctggcgctct)] were ligated into a lentiviral
plasmid backbone lentiCRISPR v2 (Addgene #52961). The clones were sequence-
verified and transfected into HEK293 cells along with the packaging plasmids
pMD2.6 (Addgene plasmid 12259) and psPAX2 (Addgene plasmid 12260). The
viral particles containing GPR35 gRNA were collected from the culture supernatant
of HEK293 cells 24–48 h post packaging and used to infect HT29/c1 cells grown on
96-well plates. The positively infected cells were selected using puromycin (2 µg/
ml) in the culture medium and were divided into three portions: (1) preserved for
later use, (2) diluted and plated on 96-well plate to obtain stable clones, and (3)
isolated genomic DNA for initial surveyor test using the primer set: survF3: 5’-
GCCCTCCCTGCTAAGAGCTG-3’ and survR3: 5’-ATGCCCTGGGAGAGCT
GG-3’. Twenty stable clones (five from each of four constructs) were expanded for
the second surveyor test. The PCR products amplified by survF/R from 12 clones
(two from each of gRNA 1A and 1B and four from each of gRNA 2A and 2B) that
were repeatedly positive on the surveyor test were sequenced. Three clones from
guides 2A and 2B whose GPR35 gene editing was confirmed through DNA
sequencing were used for further biological characterization.
Protein isolation. After 1–4 h with or without BFT treatment (100 ng/ml), cells
were washed and harvested for total cell extraction in 2% SDS in PBS with protease
inhibitor cocktail on ice. For subcellular protein extraction, cells were harvested by
trypsinization and centrifuged at 500× g for 10 min. The Thermo Scientific
subcellular protein extraction kit (87790) was used for extraction of FI (cyto-
plasmic), FII (membrane), FIII (nuclear), FIV (chromatin-bound nuclear), and FV
(cytoskeleton). Protein concentrations were measured through BCA protein assays
(Pierce). HEK293-induced and noninduced cells were lysed in lysis buffer (0.5%
Igepal CA630 in 1× PBS with 1× protease inhibitors).
Western blot. Bis-tris precast gels (4–12% gradient) were used for gel electro-
phoresis in MES buffer according to the manufacturer (BioRad). A benchmark
prestained protein ladder was used to confirm relative protein size. Gels were run
on 140 V for 5–10 min and an additional 35 min at 200 V. Proteins were trans-
ferred to a PVDF membrane in blot buffer containing 10% methanol (Invitrogen).
PVDF membranes were activated in 100% methanol and proteins were transferred
for 1.5 h at 100 V on ice. Membranes were blocked with 5% milk in Tris-buffered
saline with tween20 (TBS-T) for all antibodies, except phosphor ERK that was
blocked in 5% BSA in TBS-T. Next, primary antibody incubations were performed
according to the conditions in Table 1. Subsequently, blots were washed three times
for 10 min in TBS-T and incubated with the secondary antibodies as listed in
Table 1 (Donkey-anti-goat-HRP (Promega, V0851), goat-anti-rabbit-HRP (Jack-
son, 111-035-144), and goat-anti-mouse-HRP (Jackson, 115-035-003)). All anti-
bodies were visualized with regular ECL (Invitrogen).
ELISA (E-cadherin, IL-8). E-cadherin ELISA was performed as described by the
manufacturer (Quantikine sE-cadherin ELISA kit, R&D Systems). Epithelial
supernatants were added in a twofold dilution to the wells in assay buffer for
detection of cleaved E-cadherin.
IL-8 ELISA: The capture antibody mouse-anti-human IL-8 (BD Pharmingen
554761) was coated in 0.1 M bicarbonate buffer (pH 9.5) overnight at 4 °C. The
plate was washed 3× with 300 µl wash buffer (PBS—0.05% Tween-20). Next, the
plate was blocked with assay diluent (PBS (pH 7.0) containing 10% FCS) for 1h at
RT. After three washes with wash buffer, standards (1000 pg/ml to 15.6 pg/ml) and
cell supernatants (2× diluted) were diluted in assay diluent and applied in duplicate
to the ELISA plate and incubated for 2 h at RT. Plates were then washed and
detection antibody was added 1:500 (BD Pharmingen 554718) for 1h at RT. After
washing, poly-HRP was added at 1:10.000 and incubated for 20 min at RT. The
signal was visualized with 100 µl TMB-substrate (Pierce), and the reaction was
stopped with 2N H2SO4. Absorbance was read at 450 nm with a reference channel
at 655 nm.
Immunofluorescence and confocal imaging. β-arrestin: HT29/c1 cells on glass
coverslips were exposed to the GPR35 agonist compound 10 at 10 µM or BFT at
100 ng/ml for 30 or 60. After incubation, cells were washed with HBSS and fixed in
4% paraformaldehyde for 20 min. Cells were permeabilized with 1% Triton-X100
in PBS for 5 min. Cells were blocked with 5% BSA in PBS for 1 h at RT. Goat-anti-
beta-arrestin-2 (1:100, ab31294) in TBS-T containing 1% BSA or rabbit-anti-beta-
arrestin 1 (1:100, ab32099) was incubated overnight at 4 °C. Donkey-anti-goat
antibody labeled with Alexa fluor 568 (1:500) (Fisher scientific #A-11057) or goat-
anti-rabbit antibody labeled with Alexa 488 (1:500, Fisher scientific, #A-27034) in
TBS-T containing 1% BSA was incubated for 1h at RT for visualization. E-cadherin
was visualized with 1:200 (E2 antibody) in 5% BSA–PBS-T with secondary goat-
anti-rabbit Alexa fluor 568 (Fisher scientific, #A-11011) at 1:500. Cells were
counterstained with DAPI (1:10.000) and mounted using prolong Gold anti-fade
reagent. Cells incubated with 100 ng/ml BFT-labeled with Alexa 488 were visua-
lized with confocal microscope Olympus FV1000. All other immunofluorescence
was imaged on a confocal microscope Zeiss LSM510.
Real-time PCR. RNA was isolated from wild-type HT29/c1 cells and stably
transfected HT29/c1 cells treated or not with BFT-2 using a Qiagen RNA isolation
kit (RNeasy mini kit). For cDNA production, 1 µg of RNA was mixed with 10× RT
buffer, 100 mM dNTP Mix, 10× RT random primers, 1 µl of multiscribe reverse
transcriptase, and 1 µl of RNAse inhibitor in nuclease-free water (Applied Bio-
systems). cDNA was generated in a thermal cycler (BioRad) at 25 °C for 10 min,
Table 1 Antibody conditions western blot.
Primary antibody Provider Dilution Incubation
conditions
Secondary antibody Dilution Incubation
conditions
Mouse-anti-beta-arrestin 1 BD (610551) 1:1000 O/N 4 °C Goat-anti-mouse 1:5000 1 h RT
Goat anti-beta-arrestin 2 Abcam (ab31294) 1:2000 O/N 4 °C Donkey-anti-goat 1:2000 1 h RT
Rabbit anti-Na+K+ATPase Thermo Scientific (PA5-17251) 1:1000 O/N 4 °C Goat-anti-rabbit 1:3000 1 h RT
Mouse-anti-HDAC2 Cell signaling (3F3, #5113) 1:100 O/N 4 °C Goat-anti-mouse 1:3000 1 h RT
Mouse-anti-beta-actin Sigma Aldrich (A5441) 1:10000 2 h RT Goat-anti-mouse 1:5000 1 h RT
Rabbit anti-E-cadherin Gift from James
Nelson (Stanford University)
1:1000 O/N 4 °C Goat-anti-rabbit 1:5000 1 h RT
Rabbit anti-GFP Abcam ([E385], ab32146) 1:1000 O/N 4 °C Goat-anti-rabbit 1:5000 1 h RT
Mouse-anti-FLAG M2 Sigma Aldrich (F3165) 1:1000 O/N 4 °C Goat-anti-mouse 1:5000 1 h RT
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37 °C for 120 min, and 85 °C for 5 min. All real-time assays were amplified on a
7900 HT real-time PCR cycler (Applied Biosystems) relative to the 18S and/or
GAPDH reference genes. All primer combinations and Taqman assays are listed in
Tables 2 and 3.
Colon enteroid derivation and culture. Mouse colons were dissected from wild-
type C57Bl6 and GPR35−/− C57Bl6 mice. Two-thirds of the colon, including the
distal and middle areas, were minced into small pieces and washed in the CSC buffer.
Following an hour incubation in CSC buffer containing 20 mM EDTA with shaking
at 4 °C, the tissue pieces were filtered through a 70 µM mesh filter and washed again
by centrifugation, then suspended in 50 µl of Matrigel (Corning™ 356255), and seeded
in 24-well plates. The growth medium (supplied by The Hopkins Digestive Diseases
Basic & Translational Research Core Center) was applied after the Matrigel solidified,
and was refreshed every other day. After 7–10 days, the enteroids were expanded and
formed branches. When treated with BFT-2 from O86-5443-2-2, the growth medium
was removed and replaced with serum-free media. Purified BFT (500 ng/ml) was
added to the medium. Morphological changes of enteroids were observed and
recorded under the microscope (Nikon E200).
Mice colonization with ETBF strain O86-5443-2-2 (BFT-2-producing). The
mouse strains used in this study were C57Bl6 purchased from Jackson Laboratory
(Bar Harbor, ME, USA) or obtained as littermates of in-house breeding; GPR35
KO mice (Gpr35tm1(KOMP)Vlcg) were purchased from the Knockout Mouse
Repository (KOMP at UC Davis, CA, USA). The gpr35 gene deletion size is 923 bps
from 94,880,070 to 94,879,148 on Chromosome 1.
The ETBF-colonized mouse colitis models have been described previously23. In
brief, we administered clindamycin (0.1 gr/l) and streptomycin (5 gr/l) or cefoxitin
(100mg/ml) for 3–5 days or 1–2 days, respectively, rested for 24 h (cefoxitin model),
followed by oral inoculation with the ETBF strain 086-5443-2-2 (~1 × 107−108 bacteria
in PBS) or PBS alone (sham control) in mice at 4 weeks of age. Mice were randomly
placed in groups, making sure there were no cage effects for mice experiments. Sham
mice were housed separately from ETBF-colonized mice. We quantified fecal bacterial
colonization as colony-forming units (CFU) per gram stool. At experimental time
points, we harvested one piece each of distal and proximal colons in Trizol reagent for
RNA analysis. The remainder of the colons were Swiss-rolled, paraffin-embedded, and
subsequently sectioned for H&E staining or IHC analysis.
For the ETBF colitis mouse models, GPR35+/+, GPR35+/−, and GPR35−/−
mice were generated by breeding GPR35+/− mice. Body weight loss, indicative of
colitis severity, and death rates were monitored for the first 3–7 days of ETBF
infection while mice were kept in antibiotic-free clean cages. At the end of the
experiment, the remaining mice were sacrificed and colons were collected for RNA
or histology analysis.
All mice were kept in specific pathogen-free (SPF) conditions prior to ETBF
colonization in the JHU animal facility. The mouse protocols were approved by the
Johns Hopkins University Animal Care and Use Committee in accordance with the
Association for Assessment and Accreditation of Laboratory Animal Care
International.
Histology, inflammation, and hyperplasia scoring. Paraffin-embedded sections
of Swiss-rolled mouse colons were stained by H&E (hematoxylin and eosin) and
scored by a pathologist that was blinded for the conditions for inflammation
and hyperplasia. Inflammation was graded from 0 to 4 as 0 (normal mucosa), 1
(mild increase in inflammatory cells, no mucosal changes), 2 (moderate increase
in inflammatory cells, mild scattered proliferation focal loss of crypt archi-
tecture), 3 (severe increase in inflammatory cells, diffuse or nearly diffuse
proliferation, and focally extensive loss of crypt architecture), and 4 (complete
or nearly complete mucosal destruction). The hyperplasia was graded from 0 to
3 as 0 (normal), 1 (patchy distribution of mildly deepened crypts and slightly
thicker mucosa), 2 (moderate crypt length with hyperchromatic CEC and goblet
cell loss), 3 (severe, more than twofold, increase in crypt length with arborized
crypts, and high mitotic index such as branched crypts). Anoikis (crypt epi-
thelial cell shedding) was noted.
Statistics and reproducibility. For bar graphs of in vitro experiments concerting
expression levels, toxin scores, and IL-8-protein changes, independent one-sample
t tests were performed (two-sided). Bar graphs are plotted with mean and standard
deviations and individual data points of independent experiments are presented.
Concentration series with ML145 with readouts for toxin scores and BFT binding
at different time points were evaluated with 2-way ANOVA with Dunnett’s mul-
tiple comparison test. A p-value below 0.05 was considered significant. Each
experiment was repeated at least once independently. The majority of the experi-
ments were repeated three times. No data were excluded from the in vitro analysis.
Experimental wells for in vitro cell experiments were randomly placed in groups,
making sure there was no batch effect of experimental plates. The number of
replicates is noted in each graph and figure legends.
Survival data were compared with the log-rank (Mantel) cox test. Body weight
changes between sham and the experimental groups in GPR35 wild-type, GPR35+/−,
and GPR35−/− mice were compared with two-way ANOVA and Bonferroni post
tests to compare individual columns. Box–Whisker plots (Tukey) of the median,
range, and first and third quartile are plotted. The gene expression data between wild-
type and GPR35−/− mice were compared with Mann–Whitney U test, and data were
plotted as median with interquartile range. A P value below 0.05 was considered
significant. Mice experiments were performed at least three times for each time point,
resulting in n= 10+ per group from three independent experiments. One sham
mouse was excluded from analysis because it was cross-infected with an unknown
pathogen. The number of mice per group is defined in the figure legends.
Software and data analysis. Bar graphs and plots were generated in GraphPad
Prism (version 6, GraphPad Software Incorporated). Point mutation matrices
(PAM250, neighbor-joining) and protein alignments using Clustal W were created
in JALview version 2.11.1.0 (www.jalview.org). Western blot density measurements
were performed in Photoshop 2020 (Adobe systems incorporated). Fluorescence
images were processed in Fiji 1.51n (Wayne Rasband, National Insitute of Health).
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All data are available within the paper and Supplementary information. The source data
for the main figures are available in Supplementary Data 2. Source data are stored at the
secure servers of Radboudumc and Johns Hopkins Medical Institutions. Material requests
and correspondence about data can be addressed to Annemarie.Boleij@radboudumc.nl.
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Table 2 Primer combination for SYBR green qPCR.
Gene Species Primer forward (5’→3’) Primer reverse (5’→3’) Bp Detector
18S rRNA Human TTGACTCAACACGGGAAAC ACCCACGGAATCGAGAAAGA 81 SYBR
GPR35 a+b Human GATCAAGCTGGGCTTCTACG CAGGCTGATGCTCATGTACC 265 SYBR
GPR35b Human ACACCGTGGCAGTGAAGAG CAGGCTGATGCTCATGTACC 379 SYBR
IL-860 Human GTTGTAGTATGCCCCTAAGAG CTCAGGGCAAACCTGAGTCATC 407 SYBR
GAPDH Human TCCTGCACCACCAACTGCTTAG TGCTTCACCACCTTCTTGATGTC 341 SYBR
Table 3 Taqman assays for qPCR.
Gene Species Taqman assay Bp Detector
18S rRNA Human 4310893E 187 VIC-TAMRA
GPR35 Human Hs00271114_s1 87 FAM
ARRB2 Human Hs01034135_m1 58 FAM
ARRB1 Human Hs00244527_m1 136 FAM
GAPDH Mouse Mm99999915_g1 109 FAM
Il17a Mouse Mm00439619_m1 91 FAM
Nos2 Mouse Mm00440502_m1 66 FAM
Il6 Mouse Mm00446190_m1 78 FAM
Ifn-γ Mouse Mm00801778_m1 101 FAM
Tnf-α Mouse Mm00443260_g1 61 FAM
Il22 Mouse Mm01226722_g1 65 FAM
Cxcl5 Mouse Mm00436451_g1 75 FAM
Mt1 Mouse Mm00496660_g1 88 FAM
Mt2 Mouse Mm00809556_s1 111 FAM
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